PUBLISHER: The Business Research Company | PRODUCT CODE: 1657258
PUBLISHER: The Business Research Company | PRODUCT CODE: 1657258
Hemoglobin A1c (HbA1c) Testing Global Market Opportunities And Strategies To 2034
Hemoglobin A1c (HbA1c) testing refers to the diagnostic and monitoring tools used to measure the average blood glucose levels over the past two to three months. The test is used to diagnose diabetes, prediabetes, and evaluate the effectiveness of treatment plans in people with diabetes. It is an essential component of diabetes management and is widely used by healthcare providers to assess how well diabetes is being controlled.
The HbA1C testing market consists of sales, by entities (organizations, sole traders and partnerships), of HbA1C testing that provides a reliable indication of blood sugar levels by quantifying the percentage of glycosylated hemoglobin in the blood, offering an essential parameter for long-term glucose monitoring. The testing is primarily used by endocrinologists, general practitioners and other healthcare professionals in hospitals, clinics and diagnostic laboratories. Patients themselves may also use these tests in homecare settings for self-monitoring purposes.
The global hemoglobin A1c (HbA1c) testing market was valued at $1,410.48 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 5.00%.
Increasing Focus On Personalized Medicine
The increasing focus on personalized medicine supported the growth of the hemoglobin A1c (HbA1c) testing market during the historic period. HbA1c testing offers a long-term view of blood glucose levels over 2-3 months, enabling healthcare providers to optimize diabetes management. By integrating pharmacogenomics, personalized medicine adjusts drug selection and dosing based on genetic profiles. HbA1c results guide therapy modifications, enhancing treatment efficacy. For instance, in October 2022, according to the Personalized Medicine Coalition (PMC), a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system, more than 75,000 genetic testing products and 300 personalized medicines were present on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, personalized medicines accounted for 34% of new drug approvals by the US Food and Drug Administration and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the increasing focus on personalized medicine drove the growth of the hemoglobin A1c (HbA1c) testing market.
Advancements In Testing With Focus on High-Performance Liquid Chromatography (HPLC) Analyzers for Enhanced Diabetes Management
Leading companies in the hemoglobin A1c (HbA1c) testing market are concentrating on creating innovative solutions, including high-performance liquid chromatography (HPLC) analyzers, to enhance the accuracy, speed, and efficiency of diabetes management. HPLC analyzers are utilized to accurately measure the percentage of HbA1c in blood samples, delivering precise data for the diagnosis and ongoing monitoring of diabetes. For instance, in June 2021, Trivitron Healthcare, an India-based medical device company, launched two innovative high-performance liquid chromatography (HPLC) analyzers, the NANO H5 and NANO H110, designed for the rapid detection of glycated hemoglobin (HbA1c) and hemoglobin variants. These analyzers aim to enhance diabetes management and thalassemia diagnostics by providing results in under three minutes. The NANO H5 is a compact, fully automated HPLC analyzer that utilizes ion exchange liquid chromatography for the quantitative determination of glycated hemoglobin (HbA1c) in whole human blood. Like the NANO H5, the NANO H110 is also a compact and automated HPLC analyzer but features a dual test mode that allows for both HbA1c testing and Hb variant detection.
The global hemoglobin A1c (HbA1c) testing market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 18.1% of the total market in 2023.
Hemoglobin A1c (HbA1c) Testing Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global hemoglobin A1c (HbA1c) testing market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
The report covers the following chapters
Markets Covered:
Table of Contents
1 Executive Summary
- 1.1 Hemoglobin A1c (HbA1c) Testing - Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 Hemoglobin A1c (HbA1c) Testing Market Definition And Segmentations
- 6.4 Market Segmentation By Type
7 Major Market Trends
8 Hemoglobin A1c (HbA1c) Testing Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Hemoglobin A1c (HbA1c) Testing Volume
11 Global Hemoglobin A1c (HbA1c) Testing Market Segmentation
12 Hemoglobin A1c (HbA1c) Testing Market, Regional and Country Analysis
13 Asia-Pacific Market
14 Western Europe Market
15 Eastern Europe Market
16 North America Market
17 South America Market
18 Middle East Market
19 Africa Market
20 Competitive Landscape And Company Profiles
21 Other Major And Innovative Companies
22 Competitive Benchmarking
23 Competitive Dashboard
24 Key Mergers And Acquisitions
25 Opportunities And Strategies
26 Hemoglobin A1c (HbA1c) Testing Market, Conclusions And Recommendations
27 Appendix
